No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Idecabtagene vicleucel demonstrates higher efficacy over currently available therapies in triple-class relapsed and refractory multiple myeloma

byKathleen Lau

July 1, 2021

in StudyGraphics

Epidemiologic analysis of chilblains cohorts before and during the COVID-19 pandemic

RelatedReports

Variation noted across pre- and post-marketing studies for FDA approved devices

Hematology

FDA grants priority review for iberdomide-based myeloma regimen

March 6, 2026

Reduced gestational weight gain with lifestyle intervention

Cardiology

Replacing sedentary time with physical activity may lower risk of all-cause mortality

March 2, 2026

AI Roundup

Artificial intelligence predicts colorectal cancer in ulcerative colitis with 99% accuracy

February 20, 2026

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Weekly Rewinds

2 Minute Medicine Rewind February 16, 2026

February 16, 2026

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation

Wellness Check: Sleep

Pediatric DKA associated with recent acute care visits

Sodium-glucose cotransporter 2 inhibitors associated with reduced mortality compared with sulfonylureas in patients with type 2 diabetes

$The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor$

Isatuximab improves progression-free survival in patients receiving carfilzomib–dexamethasone treatment for multiple myeloma

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports